ClinicalTrials.gg
CompletedNCT03340480Updated May 17, 2018

The Food Effect on the Pharmacokinetics of NVP-1402

A Phase 1 interventional study of NVP-1402 in Healthy, sponsored by NVP Healthcare. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-17.

Sponsored by NVP Healthcare · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Study summary

The purpose of this study is to evaluate the food effect on the pharmacokinetics of NVP-1402 in healthy male volunteers.

Read the detailed description

This study is designed as randomized, open-label, single oral dose, two-treatment, two sequence crossover active-controlled and crossover assignment for evaluate the food effect on the pharmacokinetics of NVP-1402 in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

NVP Healthcare is the lead sponsor of 22 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males
  • No history of medical disorder
  • Capable of consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • History of hypersensitive reactions to study drug or other related drugs
  • Any significant abnormality found during screening
  • Any significant medical history
  • History of alcohol abuse, smoking continuously
  • History of drug abuse
  • surgery within 4 weeks prior to administration of the study drug
  • Participation in another clinical trial within 3 months prior to administration of the study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    NVP-1402-1

    NVP-1402 was administered once a day for 24 hours

    Drug: NVP-1402

  • Experimental
    NVP-1402-2

    NVP-1402 was administered once a day for 24 hours

    Drug: NVP-1402

Interventions

  • DrugNVP-1402

    Oral

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of plasma: Cmax

    Maximum measured concentration of the analyte in plasma

    Time frame: up to 24 hours after administration

  2. Pharmacokinetics of plasma: AUClast

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point

    Time frame: up to 24 hours after administration

Secondary outcomes

  1. Pharmacokinetics of plasma: AUCinf

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity

    Time frame: up to 24 hours after administration

  2. Pharmacokinetics of plasma: Tmax

    Time from dosing to the maximum measured concentration of the analyte in plasma

    Time frame: up to 24 hours after administration

  3. Pharmacokinetics of plasma: t1/2

    Terminal half-life of the analyte in plasma

    Time frame: up to 24 hours after administration

07

Study locations

1 site
  • Navipharm
    Suwon-si, Gyeonggi-do 16209, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jan 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 13, 2017
StartActual
Dec 12, 2017
Primary completionActual
Jan 8, 2018
CompletionActual
May 2, 2018
Last update
May 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03340480
Lead sponsor
NVP Healthcare
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Dec 12, 2017
Primary completion
Jan 8, 2018
Completion
May 2, 2018
Last update
May 17, 2018

Study contacts

D Seong Shin
principal investigator · Gachon University Gil Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion